Trials / Not Yet Recruiting
Not Yet RecruitingNCT07149181
Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery
A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,000 (estimated)
- Sponsor
- Liaoning Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the efficacy and safety of chemotherapy combined with or without immunotherapy as postoperative adjuvant regimens in patients with resectable gastric cancer/adenocarcinoma of the esophagogastric junction after radical surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SOX plus PD-1 inhibitor | SOX or XELOX plus PD-1 inhibitor |
| DRUG | SOX Chemotherapy | SOX or XELOX |
Timeline
- Start date
- 2025-08-31
- Primary completion
- 2025-08-31
- Completion
- 2028-09-30
- First posted
- 2025-08-29
- Last updated
- 2025-08-29
Source: ClinicalTrials.gov record NCT07149181. Inclusion in this directory is not an endorsement.